Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer

Abstract

Background: The evaluation of intravitreal bevacizumab treatment for delayed radiationmaculopathy and papillopathy after irradiation for maxillary sinus cancer.Case report: A patient with radiation maculopathy and papillopathy was treated with intravitrealbevacizumab (1.25 mg). Main outcome measures included fundus photography, angiography,and optical coherence tomography (OCT). Two weeks after intravitreal bevacizumab, visualacuity improved from 0.4 to 1.2. Fundus examination revealed decreased disc swelling, peripapillaryhemorrhage, and macular edema. OCT demonstrated complete resolution of serousretinal detachment. At the 12-month follow-up, there was no exudation recurrence. No ocularor systemic side effects were observed.Conclusion: Intravitreal bevacizumab can be used to treat radiation maculopathy andpapillopathy.Antivascular endothelial growth factor therapy may decrease tissue injury associatedwith radiation vasculopathy. © 2011 Gondo et al, publisher and licensee Dove Medical Press Ltd.